News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis to Voluntarily De-List from Nasdaq
Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced a decision to voluntarily de-list from the Nasdaq Global Market (“Nasdaq").
Pharmaxis has recently completed a review of the demand from existing and potential international investors for the secondary listing of its American Depositary Shares...
Read full media release - pdf
Pharmaxis Closes Share Purchase Plan
Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced it had raised A$7.2 million from its
Share Purchase Plan which closed on 24 June 2009. Shareholders of the company were
given the opportunity to purchase up to $5,000 worth of shares each at the $2.35 price
paid by institutional investors in the recent placement.
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Pharmaceutical company Pharmaxis (ASX:PXS, Nasdaq:PXSL) is pleased to announce that
additional results of its recently completed international Phase III trial of Bronchitol in patients
with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in
Brest, France.